Budget impact analysis of implementation of biosimilars in a private health insurance company of large size in Southern Brazil 

Author(s): Rafael Gama, MD, MBA, Associate Professor Valderilio Feijó Azevedo, MSc, MD, PhD, Paula Heberle, MBA, Sergio Mauricio Menoncin, MSc, Daniela Toigo, MBA, Fabiana Aguiar, PG, Josymar Nascimento Júnior, MD, Ana Carolina Maciel, PG, Ricardo Luiz Pereira Bueno, BA, MHA, PhD

Study objectives: To evaluate the budget impact of implementing a physician-led biosimilar switching programme within a large private health insurance company in Southern Brazil. Methods: This retrospective observational study analysed real-world data from a private payer perspective over 24 months (November 2022–October 2024). Six biologicals were included: infliximab, adalimumab, etanercept, rituximab, trastuzumab, and bevacizumab. In year […]

Read more →